Skip to Main Content

Paper Details

Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective.
J Natl Cancer Inst
18
2022
Denosumab, Larotrectinib, PROs, Patient, Pediatric, Pediatric Cancer, Selumetinib, Tisagenlecleucel, cancer, patient, patients, pediatric cancer
Author NameAffiliation
Gregory H ReamanOncology Center for Excellence
Gregory H ReamanOncology Center for Excellence
  • 1 - 2

Datasets

Release 1.2